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mechanism of action of CQ in human
cancer cell lines in which PUMA is not
chromosomally deleted and p53-depen-
dent induction of PUMA is intact. If this
mechanism is confirmed, measurement
of PUMA expression before treatment
could identify patients who might be
susceptible to CQ-based therapies, and
serial measurement of PUMA in tumor
tissue could serve as a biomarker of CQ
efficacy. Further dissection of the mole-
cular mechanism by which CQ stabi-
lizes PUMA could yield new targets for
other therapeutics. As more and more
evidence supports the testing of lysoso-
mal autophagy inhibitors in cancer, the
puzzling pieces of CQ’s mechanism of
action should be put together, hopefully
avoiding the fate that CQ derivatives
had in other diseases.
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Skin-Specific Drug Delivery: A Rapid
Solution to Skin Diseases?
Christian D. Sadik1 and Detlef Zillikens1
In this issue of the Journal of Investigative Dermatology, Kouno et al. achieve skin-
specific drug delivery using an antibody to deliver substances in a highly specific
manner to nontransformed cells. They make use of a nonpathogenic anti-
desmoglein 3 autoantibody that had been derived from a patient with pemphigus
vulgaris to deliver drugs to the surface of keratinocytes. This approach may turn
out to be a new ‘‘magic bullet’’, thereby revolutionizing the therapy of skin
disease. The authors then used a conjugate of this antibody with a new drug
entity, TNF-related apoptosis-inducing ligand, to demonstrate, as a proof of
principle, that their approach has the potential to facilitate the treatment of both
cancerous and inflammatory skin diseases.
Journal of Investigative Dermatology (2013) 133, 2135–2137. doi:10.1038/jid.2013.231
Systemic immunosuppression—an
avoidable risk?
Autoimmune diseases constitute a com-
plex and diverse array of diseases, fea-
turing either systemic or organ-specific
inflammation. The latter is more com-
mon and is sometimes restricted to skin.
However, therapeutic strategies in both
systemic and organ-specific autoim-
mune diseases usually include the use
of systemic immunosuppressive drugs.
Systemic immunosuppression bears
numerous unwanted consequences for
patients, including increased risk of
infection and malignancy. Furthermore,
the drugs that are used may also be
associated with other severe side effects,
including diabetes, hypertension, and
pneumonitis. With regard to these pos-
sible sequelae of systemic immunosup-
pression on one the hand and the organ
restriction of inflammation on the other,
the obvious question is how to circum-
vent these disadvantages of systemic
immunosuppression. Tissue-specific
drug delivery, restraining immunosup-
pression to disease-affected tissues,
may be the ‘‘magic bullet’’ that solves
this concern.
Tissue-specific drug delivery
Tissue-specific drug delivery aims at
increasing the concentration of a drug
in a specific target tissue compared with
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the rest of the body. Generally, this may
be achieved by using structural proper-
ties of the drug or by its pharmaceutical
formulation. Tissue-specific drug deliv-
ery may prevent adverse off-target
effects, drug toxicities, and unnecessary
systemic immunosuppression, while
at the same time providing increased
therapeutic efficacy. Moreover, tissue-
specific delivery may also increase
the number of indications for drugs
whose use in some diseases may have
been thwarted by low bioavailability
in affected tissues and by prohibi-
tively high toxicities in the rest of the
body.
The concept of tissue-specific drug
delivery is old; linking a drug to
an antibody to achieve tissue-specific
delivery was first attempted by 1958
when methotrexate was linked to an
antibody in an attempt to specifically
deliver it to leukemic cells in mice.
However, at present, tissue-specific drug
delivery, especially into nontransformed
tissues, remains in its infancy. Although
in oncology tumor-specific or tumor-
enhanced antigen expression is already
exploited to deliver antibody-coupled
drugs to tumors, targeting nontrans-
formed cells has turned out to be more
challenging. Many approaches have
been attempted to meet this challenge,
such as the use of drug-loaded lipo-
somes equipped on their surface with
ligands or receptors to gain selectivity
for target cells. Another approach
exploits organ-specific differences in
the microstructure of the vascular
endothelium. For this purpose, homing
proteins, i.e., proteins that bind selec-
tively to the endothelium of a target
organ have been sought. Substances
coupled to these homing proteins may
enable tissue-specific drug delivery.
However, until now, none of these
methods have reached a level that is
useful for patients.
Tissue-specific drug delivery into skin
In this issue of The Journal of
Investigative Dermatology, Kouno et al.
(2013) report the development of a new
strategy for target-specific drug delivery
into the skin by taking advantage of an
autoantibody directed against desmo-
glein 3 (Dsg3). Dsg3 is a cadherin-type
adhesion molecule expressed on epithe-
lial cells in skin and mucous mem-
branes, which establishes cell–cell
contacts between epithelial cells to
produce tissue integrity (Mahoney
et al., 1999). Autoantibodies directed
against Dsg3 initiate pemphigus
vulgaris, a severe and difficult-to-treat
autoimmune blistering skin disease, one
that exhibits erosions on skin and
mucous membranes. To develop a
drug that was specific for keratino-
cytes, the authors used a monoclonal,
nonpathogenic anti-Dsg3 autoantibody
(designated ‘‘Px44’’) that had been ob-
tained from a patient with pemphigus
vulgaris (Payne et al., 2005). This
approach is innovative in two ways:
first, the antibody would be specific for
nontransformed cells, whereas earlier
approaches had used antibodies
against cancer cells. Second and ironi-
cally, the antibody was derived from
a patient suffering from a severe auto-
immune disease.
The authors use a single-chain vari-
able fragment (scFvs) of Px44 (anti-Dsg3
scFvs). Importantly, the anti-Dsg3 scFvs
is only 25 kDa in size, and it does not
include the antibody effector region,
allowing it to provide high tissue acces-
sibility and to avoid antibody-induced
inflammation. Furthermore, as anti-
Dsg3 scFvs is fully human, the risk that
this protein might elicit an immune
response, which biologicals commonly
do, is negligible. These properties
make anti-Dsg3 scFvs exploitable as a
mechanism of delivering drugs via sys-
temic administration or even locally into
skin. The authors provided evidence that
anti-Dsg3 scFvs does conjugate with
keratinocytes by showing localization
of a GFP label to keratinocyte surfaces
in human skin ex vivo explants and in
murine skin after intradermal or intra-
venous injection of the anti-Dsg3 scFvs-
GFP conjugate. These experiments
provide the proof of principle for
anti-Dsg3 scFvs–mediated drug delivery
to keratinocytes. On the basis of these
findings, there are some interesting
questions that can now be addressed.
They include specificity studies of anti-
Dsg3 scFvs for keratinocytes, because
Dsg3 is also expressed in mucous mem-
branes. It can be expected that anti-
Dsg3 scFvs will bind to Dsg3 that is
expressed by mucous membranes that
have squamous epithelia as well. If so,
this may be a potential source of side
effects. Specifically, Px44–TNF-related
apoptosis-inducing ligand (Px44–TRAIL)
conjugates, which were used later in
this study and were shown to induce
apoptosis in hyperproliferative cells,
may precipitate disease in mucous
membranes given their high proliferative
rates. Before considering anti-Dsg3
scFvs conjugates seriously for use in
human patients, it must be shown
that they also bind with sufficient
avidity to the surface of keratinocytes
after systemic administration into
humans. Understandably, this question
was beyond the scope of the present
study.
TRAIL for treatment of skin diseases
Kouno et al. (2013) also engineered a
conjugate of the TRAIL and anti-Dsg3
scFv, which they designated ‘‘Px44–
TRAIL’’. TRAIL is a protein belonging
to the TNF superfamily. In humans,
it binds to TRAIL death receptors,
Clinical Implications
 Tissue-specific drug targeting into nontransformed skin is feasible and
may improve substantially the treatment of skin diseases while minimizing
adverse effects and avoiding systemic immunosuppression.
 Anti-Dsg3 scFv can be used in vivo to ‘‘home’’ structurally diverse
compounds specifically onto keratinocyte surfaces.
 Px44–TRAIL induces apoptosis specifically in proliferating keratinocytes
and inhibits activated T cells; hence, it bears potential as a therapeutic tool
for the treatment of several skin diseases, including psoriasis, lichen
planus, and (pre-)cancerous skin lesions.
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and subsequently induces apoptosis in a
caspase-dependent manner, preferen-
tially in tumor cells. Moreover, it can
exert both pro- and anti-inflammatory
effects and may have a role in processes
such as host defense and pathogenesis
of inflammatory diseases on one hand
and establishment of immune privi-
lege in certain tissues on the other
(Niederkorn, 2006; Benedict and
Ware, 2012). First clinical trials using
TRAIL as drug in cancer treatment are
currently under way. Kouno et al.
choose TRAIL as the first possible thera-
peutic compound conjugated to anti-
Dsg3 scFv, because they saw potential
not only for therapeutic use of TRAIL in
the treatment of skin cancers but also
in the treatment of inflammatory skin
diseases, which are often characterized
by marked T cell infiltration into the
skin and keratinocyte hyperproliferation,
as seen in most pronounced ways in
psoriasis.
The authors show that Px44–TRAIL
induces apoptosis in proliferating kera-
tinocytes in vivo and in vitro, while
sparing differentiated keratinocytes,
and demonstrate that it inhibits IFN-g
release from activated T cells in vitro,
suggesting an anti-inflammatory effect of
TRAIL and the possibility of the genera-
tion of an immune privileged micro-
environment in the skin. These findings
make Px44–TRAIL a drug candidate
with a dual effector mechanism comb-
ing inhibition of keratinocyte and mela-
nocyte hyperproliferation with local
immunosuppression. Therefore, Px44–
TRAIL may be suitable to treat both
inflammatory skin diseases, particularly
psoriasis with its keratinocyte hyper-
proliferation and its pivotal pathogenic
role of skin-infiltrating T cells, as well as
cancerous and precancerous skin
lesions, such as actinic keratosis, lentigo
maligna, and head and neck squamous
cell carcinoma.
Kouno et al. (2013) do not progress
to address the therapeutic potential
of Px44–TRAIL in an in vivo model
of skin inflammation. Examining the
therapeutic potential of Px44–TRAIL in
mouse models reflecting psoriasis
will help understand the net effect of
Px44–TRAIL in vivo and to scrutinize
its therapeutic potential. Although
Px44–TRAIL inhibited activated T cells
in vitro, given the possibly opposite
overall effects of Px44–TRAIL on immune
responses (Benedict and Ware, 2012;
Rethi and Eidsmo, 2012), even a
proinflammatory net effect in the skin
in vivo cannot be excluded at this point.
In addition, the study found Px44–TRAIL
to inhibit TH1 skewed T cells in vitro.
With regard to the recently purported
predominant importance of TH17 cells
in many autoimmune diseases, includ-
ing psoriasis, an investigation into the
effects of Px44–TRAIL on this T cell
subtype is warranted.
Future perspectives
Kouno et al. (2013) succeed in
developing the first antibody-mediated
tissue-specific delivery drug for
nontransformed cells, opening new
avenues for therapeutic strategies. This
achievement should help tissue-specific
drug delivery to gain new momentum.
Anti-Dsg3 scFv earmarks therapeutics
with a ‘‘zip code’’ that promises drug
delivery predominantly to skin. Intri-
guingly, anti-Dsg3 scFv can be
conjugated with structurally diverse
substances in a modular manner to
obtain many new drug compounds. It
can be conjugated with small molecules,
including prodrugs, further enhancing
skin specificity, or with macro-
molecules, including proteins, such as
cytokines, antibodies, and enzymes.
Additional advantages of this method
may emerge, including the possibility
of prolonged half-life following entry
into a target tissue.
Although organ-specific therapy
would be an asset, it will also have its
limits. First, we often do not know
whether the disease-driving processes
of skin disease primarily occur in the
skin. Furthermore, we are just beginning
to grasp the intricate interplay between
the other organs and skin. Unexpected
discoveries, such as the contributions of
brain and liver to inflammation in
remote organs, suggest that there is still
much to learn.
p38 MAPK activation in keratinocytes
after binding of pathogenic anti-Dsg 3
autoantibodies is an important event in
the pathogenesis of pemphigus vulgaris
(Berkowitz et al., 2006), but the clinical
use of p38 MAPK inhibitors has been
hampered by a poor safety profile among
the currently available p38 MAPK inhi-
bitors; it includes, among others, hepato-
toxic effects and renal and cerebral
dysfunction (Zhang et al., 2007). Intri-
guingly, a nonpathogenic anti-Dsg3 auto-
antibody delivering p38 MAPK inhibitors
specifically to keratinocytes may be
exactly what patients with pemphigus
vulgaris need.
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